---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:16:10.754449'
end_time: '2025-12-14T17:21:25.043390'
duration_seconds: 314.29
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: RASA3
  gene_symbol: RASA3
  uniprot_accession: Q14644
  protein_description: 'RecName: Full=Ras GTPase-activating protein 3; AltName: Full=GAP1(IP4BP);
    AltName: Full=Ins P4-binding protein;'
  gene_info: Name=RASA3;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: C2_dom. (IPR000008); C2_domain_sf. (IPR035892); PH-like_dom_sf.
    (IPR011993); PH_domain. (IPR001849); Ras_GTPase. (IPR039360)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 10
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q14644
- **Protein Description:** RecName: Full=Ras GTPase-activating protein 3; AltName: Full=GAP1(IP4BP); AltName: Full=Ins P4-binding protein;
- **Gene Information:** Name=RASA3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** C2_dom. (IPR000008); C2_domain_sf. (IPR035892); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849); Ras_GTPase. (IPR039360)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "RASA3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'RASA3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **RASA3** (gene ID: RASA3, UniProt: Q14644) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q14644
- **Protein Description:** RecName: Full=Ras GTPase-activating protein 3; AltName: Full=GAP1(IP4BP); AltName: Full=Ins P4-binding protein;
- **Gene Information:** Name=RASA3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** C2_dom. (IPR000008); C2_domain_sf. (IPR035892); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849); Ras_GTPase. (IPR039360)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "RASA3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'RASA3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **RASA3** (gene ID: RASA3, UniProt: Q14644) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and identity verification
- Target verified: Human RASA3 (UniProt Q14644), also known as GAP1(IP4BP)/GAP1IP4BP, a Ras-GTPase–activating protein family member with C2, central RasGAP-related catalytic domain, and a PH domain. Contemporary platelet literature describes these domains and their roles in membrane binding and regulation, confirming concordance with the UniProt domain annotations (C2, RasGAP-related, PH) and the human organism context (Homo sapiens) (odonoghue2024rolesofg pages 18-19, odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024). 

Comprehensive research report on RASA3 (human; UniProt Q14644)

1) Key concepts and definitions with current understanding
- Molecular identity and domains: RASA3 is a small GTPase–activating protein (GAP) in the RasGAP family that inactivates small GTPases by accelerating GTP hydrolysis. In human platelets and megakaryocytes, RASA3 contains an N‑terminal C2 domain, a central RasGAP-related catalytic domain, and a C‑terminal PH domain. The C2 and PH domains contribute to membrane association and are integral to regulation of its GAP activity at the plasma membrane (odonoghue2024rolesofg pages 18-19, odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).
- Enzymatic reaction and substrate specificity: RASA3 functions as a dual-specificity GAP that prominently targets Rap1 and also exhibits activity toward Ras (reported as H‑Ras in platelet-oriented sources). In platelets, RASA3 reduces Rap1‑GTP to restrain integrin activation; genetic and biochemical evidence place RAP1 as the primary physiological substrate in this lineage (stefanini2015rasa3isa pages 1-2, odonoghue2024rolesofg pages 10-11). URLs: https://doi.org/10.1172/jci77993 (Apr 2015); https://doi.org/10.1042/BSR20231420 (May 2024).
- Subcellular localization and membrane targeting: In platelets, RASA3 is functionally linked to the plasma membrane via its lipid-binding PH domain. P2Y12–Gi–PI3K signaling generates PI(3,4,5)P3 that promotes RASA3 membrane association; in this context, RASA3 is proposed to become functionally inhibited to allow sustained Rap1‑GTP during platelet activation. Proteomic evidence identifies RASA3 as a PI(3,4,5)P3‑binding protein. Some studies observed context-dependent membrane association that is not uniformly PI3K-sensitive, indicating cell state–dependent regulation (odonoghue2024rolesofg pages 18-19, stefanini2015rasa3isa pages 8-9). URLs: https://doi.org/10.1042/BSR20231420 (May 2024); https://doi.org/10.1172/jci77993 (Apr 2015).

2) Recent developments and latest research (prioritize 2023–2024)
- 2024 platelet GAPs review: A curated synthesis of G proteins and GAPs in platelets details RASA3’s roles, lipid regulation, and quantitative proteomics. It reports human platelet abundance (~8,293 copies/platelet) and curated phosphosite counts (~12), and reiterates RASA3 specificity for Rap1 (with reported H‑Ras activity), its inhibitory role on platelet adhesion/aggregation, and its linkage to P2Y12→PI3K→PIP3 pathways (odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).
- 2023 T‑cell trafficking: Genetic deletion of Rasa3 together with Sipa1 in mouse T cells caused spontaneous Rap1 activation and excessive adhesion, leading to sequestration in lung capillaries; blockade of LFA‑1 or deletion of talin1 or Rap1 rescued the phenotype. Lymph node entry and motility remained intact, but egress was delayed, implicating Rasa3‑mediated Rap1 inactivation as critical for proper lymphocyte recirculation. These findings update RASA3’s physiological scope in hematopoietic trafficking beyond platelets (horitani2023thecriticalrole pages 1-2). URL: https://doi.org/10.3389/fimmu.2023.1234747 (Jul 2023).
- 2024 synthesis of platelet mechanisms: The same 2024 review consolidates earlier mechanistic observations that ADP–P2Y12 activation drives PI3K-dependent modulation of RASA3 to sustain Rap1 activity during platelet activation; it also notes conflicting observations on membrane localization control, highlighting active debate on context-specific regulation (odonoghue2024rolesofg pages 18-19). URL: https://doi.org/10.1042/BSR20231420 (May 2024).

3) Current applications and real-world implementations
- Antiplatelet therapy mechanism context: The platelet model positions RASA3 as a key negative regulator of CalDAG‑GEFI→Rap1 signaling. P2Y12 antagonists (a clinical antiplatelet class) would be expected to maintain RASA3 activity and thereby destabilize thrombus growth by promoting Rap1‑GTP turnover. Experimental mouse work supports that P2Y12 inhibition prevents the inactivation of RASA3, which contributes mechanistically to thrombus destabilization under antiplatelet therapy (stefanini2015rasa3isa pages 8-9). URL: https://doi.org/10.1172/jci77993 (Apr 2015).
- Quantitative proteomics for target assessment: Human platelet proteomic copy-number estimates and phosphosite annotations for RASA3 provide a quantitative framework for systems pharmacology and signaling models of platelet activation/inhibition (odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).

4) Expert opinions and analysis from authoritative sources
- Consensus model in platelets: Expert synthesis in 2024 concludes that RASA3 is a central Rap1/Ras GAP in platelets, that it restrains platelet adhesion and aggregation by reducing Rap1‑GTP, and that it is regulated by phosphoinositide signaling downstream of P2Y12–Gi–PI3K. The review also flags experimental inconsistencies in membrane targeting, suggesting regulation is context-dependent and may vary with experimental systems (odonoghue2024rolesofg pages 18-19, odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).
- Genetic causality for hematologic phenotypes: The JCI study established RASA3 as a critical inhibitor of Rap1-dependent platelet activation in vivo. Rasa3 loss or reduction led to hyperresponsive platelets, constitutive integrin activation, shortened platelet lifespan with increased turnover, and thrombocytopenia; removal of the upstream Rap1 GEF (CalDAG‑GEFI) normalized Rap1 signaling and platelet counts, demonstrating a causal RASA3→Rap1 axis in platelet homeostasis (stefanini2015rasa3isa pages 1-2, stefanini2015rasa3isa pages 8-9). URL: https://doi.org/10.1172/jci77993 (Apr 2015).
- Immunocyte trafficking: 2023 mechanistic genetics in T cells show that Rasa3-mediated Rap1 inactivation is essential to prevent pathological adhesion during microvascular transit and to ensure efficient egress from lymph nodes, refining our understanding of RASA3’s role in integrin-dependent leukocyte trafficking (horitani2023thecriticalrole pages 1-2). URL: https://doi.org/10.3389/fimmu.2023.1234747 (Jul 2023).

5) Relevant statistics and data from recent studies
- Protein copy number and PTMs in human platelets: RASA3 ≈ 8,293 copies per platelet; ~12 phosphosites curated in the platelet proteome table (Bioscience Reports 2024) (odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).
- Functional positioning among platelet GAPs: The 2024 review highlights RASA3 as abundant among platelet GAPs and functionally assigned to Rap1/H‑Ras regulation with direct consequences for αIIbβ3 integrin activation and platelet aggregation (odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).
- In vivo hematologic phenotypes (mouse): Rasa3 reduction or loss causes marked thrombocytopenia due to accelerated platelet clearance and shortened lifespan; CalDAG‑GEFI deletion abrogates basal Rap1 activation and rescues counts, quantitatively linking RASA3 activity to platelet homeostasis in vivo (stefanini2015rasa3isa pages 1-2, stefanini2015rasa3isa pages 8-9). URL: https://doi.org/10.1172/jci77993 (Apr 2015).

Mechanistic pathway integration
- Core pathway: In resting platelets, RASA3 counters the CalDAG‑GEFI→Rap1 pathway to maintain low Rap1‑GTP, thereby keeping talin-dependent αIIbβ3 integrin in an inactive state. Upon activation, ADP acting via P2Y12–Gi engages PI3K to produce PI(3,4,5)P3; RASA3 is recruited to the membrane and becomes functionally inhibited, limiting Rap1‑GTP turnover and enabling sustained integrin activation and platelet aggregation. This process is reversible or blunted when P2Y12 or PI3K are inhibited, an effect that in part reflects preserved RASA3 activity (stefanini2015rasa3isa pages 1-2, stefanini2015rasa3isa pages 8-9, odonoghue2024rolesofg pages 18-19). URLs: https://doi.org/10.1172/jci77993 (Apr 2015); https://doi.org/10.1042/BSR20231420 (May 2024).
- Broader hematopoietic trafficking: In T cells, Rasa3 (with Sipa1) tempers Rap1-driven integrin adhesion during pulmonary capillary transit and is required for lymph node egress; loss results in excessive adhesion and trafficking defects without impairing chemokine responsiveness, emphasizing precise spatiotemporal GAP control of Rap1 (horitani2023thecriticalrole pages 1-2). URL: https://doi.org/10.3389/fimmu.2023.1234747 (Jul 2023).

Physiological roles and tissue contexts
- Platelets and megakaryocytes: RASA3 is highly expressed in human platelets, acts as the key Rap1 GAP to maintain quiescence, and prevents premature integrin activation and aggregation. Mouse genetics show that Rasa3 deficiency yields hyperactive platelets, thrombocytopenia, and bleeding phenotypes; these effects map to the Rap1–talin–αIIbβ3 axis (stefanini2015rasa3isa pages 1-2, odonoghue2024rolesofg pages 17-18, odonoghue2024rolesofg pages 10-11). URLs: https://doi.org/10.1172/jci77993 (Apr 2015); https://doi.org/10.1042/BSR20231420 (May 2024).
- Erythropoiesis/megakaryopoiesis (inference from genetics): Mouse studies cited by recent immunology work and platelet literature associate Rasa3 loss with anemia and thrombocytopenia, indicating roles in erythroid and megakaryocytic lineages mediated through Rap1 signaling; these data support but do not by themselves delineate all steps in human erythropoiesis (horitani2023thecriticalrole pages 1-2, stefanini2015rasa3isa pages 1-2). URLs: https://doi.org/10.3389/fimmu.2023.1234747 (Jul 2023); https://doi.org/10.1172/jci77993 (Apr 2015).
- Lymphocyte trafficking: Rasa3 is necessary to terminate Rap1 signaling to avoid pathological adhesion in lung microvasculature and to enable timely egress from lymph nodes, underscoring its role in integrin-dependent immune cell trafficking (horitani2023thecriticalrole pages 1-2). URL: https://doi.org/10.3389/fimmu.2023.1234747 (Jul 2023).
- Endothelium: Direct endothelial cell-autonomous roles are not resolved by the gathered sources; platelet–endothelial interactions are indirectly implicated through integrin activation and vascular hemostasis mechanisms (odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).

Human genetics and disease associations
- Established in vivo causality (mouse): Naturally occurring and engineered Rasa3 variants produce severe thrombocytopenia and anemia with accelerated platelet turnover; platelet phenotypes are tightly linked to Rap1 deregulation and integrin αIIbβ3 activation (stefanini2015rasa3isa pages 1-2). URL: https://doi.org/10.1172/jci77993 (Apr 2015).
- Human variant evidence: The gathered 2023–2024 sources reviewed here do not provide definitive human pathogenic variant evidence for RASA3; disease relevance is primarily supported by mechanistic homology and strong mouse genetics. Thus, clinical translation remains inferential in these specific sources (odonoghue2024rolesofg pages 10-11, horitani2023thecriticalrole pages 1-2). URLs: https://doi.org/10.1042/BSR20231420 (May 2024); https://doi.org/10.3389/fimmu.2023.1234747 (Jul 2023).

Translational implications
- Antiplatelet pharmacology: The RASA3-centered model rationalizes how P2Y12 antagonists (standard-of-care antiplatelets) may preserve RASA3 activity and diminish sustained Rap1 signaling, providing a mechanistic underpinning for thrombus instability under therapy (stefanini2015rasa3isa pages 8-9). URL: https://doi.org/10.1172/jci77993 (Apr 2015).
- Biomarker and systems modeling: Quantitative copy numbers and phosphosite annotations facilitate modeling of platelet activation networks and may assist in identifying states of heightened thrombotic or bleeding risk associated with altered RASA3 signaling (odonoghue2024rolesofg pages 10-11). URL: https://doi.org/10.1042/BSR20231420 (May 2024).

Concise evidence summary
| Category | Key finding | Mechanistic/experimental evidence | Year & Source (journal) | URL | Citation IDs |
|---|---|---|---:|---|---|
| Identity & domains | Human RASA3 (GAP1/IP4BP) contains N-terminal C2 domain, central Ras-GAP (RasGRD) domain, and C-terminal PH domain; C2/PH implicated in membrane binding and regulation of GAP activity. | Domain roles and membrane-binding properties described in platelet-focused review (C2/PH required for membrane interaction). | 2024, Bioscience Reports | https://doi.org/10.1042/BSR20231420 | (odonoghue2024rolesofg pages 18-19) |
| Enzymatic function & substrate specificity | Acts as a GTPase-activating protein (GAP) with activity against Rap1 (primary) and reported activity toward Ras/H‑Ras (dual specificity reported). | Mouse genetic and biochemical data showing RASA3 reduces Rap1-GTP levels in platelets; review notes Rap1 and H‑Ras specificity. | 2015, J Clin Invest; 2024, Bioscience Reports | https://doi.org/10.1172/jci77993 ; https://doi.org/10.1042/BSR20231420 | (stefanini2015rasa3isa pages 1-2, odonoghue2024rolesofg pages 18-19) |
| Regulators & membrane targeting | Regulated by Gi-coupled P2Y12 → PI3K signaling: PI3K-generated PIP3 recruits/inactivates RASA3 via PH domain; PH domain reported to bind PIP2/PIP3; some context-dependent differences reported for PM association. | Platelet experiments and reviews linking P2Y12/PI3K to RASA3 membrane recruitment and functional inactivation; PI3K inhibitors alter RASA3 regulation (with some conflicting observations). | 2015, J Clin Invest; 2024, Bioscience Reports | https://doi.org/10.1172/jci77993 ; https://doi.org/10.1042/BSR20231420 | (stefanini2015rasa3isa pages 8-9, odonoghue2024rolesofg pages 18-19) |
| Core signaling pathway roles | RASA3 restrains Rap1 → talin → αIIbβ3 integrin inside-out activation in platelets; loss of RASA3 → elevated Rap1-GTP and constitutive integrin activation leading to premature platelet adhesion/aggregation. | Mouse knockout/mutant platelet phenotypes, biochemical Rap1-GTP measurements, and rescue experiments (CalDAG‑GEFI deletion reverses thrombocytopenia) demonstrating RASA3 as critical RAP-GAP in platelet signaling. | 2015, J Clin Invest; 2024, Bioscience Reports | https://doi.org/10.1172/jci77993 ; https://doi.org/10.1042/BSR20231420 | (stefanini2015rasa3isa pages 1-2, odonoghue2024rolesofg pages 17-18) |
| Physiological roles | Essential for platelet quiescence/homeostasis; implicated in erythropoiesis/megakaryopoiesis (mouse mutants show anemia/thrombocytopenia); regulates lymphocyte trafficking (T cell pulmonary transit and lymph node egress via Rap1 inactivation). | Mouse genetic models (Rasa3 mutants, tissue-specific deletions), T-cell conditional double knockout with Sipa1 showing Rap1 hyperactivation, lung sequestration and egress defects. | 2015, J Clin Invest; 2023, Frontiers in Immunology | https://doi.org/10.1172/jci77993 ; https://doi.org/10.3389/fimmu.2023.1234747 | (stefanini2015rasa3isa pages 1-2, horitani2023thecriticalrole pages 1-2) |
| Recent 2023–2024 updates | 2023: Rasa3 (with Sipa1) identified as critical Rap1-GAPs in T cells controlling pulmonary transit and egress; 2024: platelet-focused reviews consolidate RASA3 regulation by P2Y12/PI3K and report proteomic annotations (binding partners, phosphosites). | Horitani et al. (2023) T‑cell genetic studies; 2024 review summarizes platelet proteomics, lipid binding, and functional context. | 2023, Frontiers in Immunology; 2024, Bioscience Reports | https://doi.org/10.3389/fimmu.2023.1234747 ; https://doi.org/10.1042/BSR20231420 | (horitani2023thecriticalrole pages 1-2, odonoghue2024rolesofg pages 10-11) |
| Quantitative data | RASA3 abundance in human platelets reported ≈ 8,293 copies/platelet; table entry reports ~12 phosphorylation sites annotated. | Proteomics/curated platelet protein table in 2024 review. | 2024, Bioscience Reports | https://doi.org/10.1042/BSR20231420 | (odonoghue2024rolesofg pages 10-11) |
| Human genetics / disease associations | Mouse Rasa3 missense alleles (e.g., G125V, "scat") cause severe thrombocytopenia and anemia; mouse/chimera data link RASA3 loss to hematopoietic defects; direct human pathogenic variants not established in these sources. | Experimental mouse genetics (mutants, chimeras) demonstrating causal phenotypes; human disease relevance inferred but not directly proven in these cited works. | 2015, J Clin Invest; 2023, Frontiers in Immunology | https://doi.org/10.1172/jci77993 ; https://doi.org/10.3389/fimmu.2023.1234747 | (stefanini2015rasa3isa pages 1-2, horitani2023thecriticalrole pages 1-2) |


*Table: Concise, evidence-linked summary of molecular features, regulation, pathways, physiological roles, recent updates, quantitative data, and genetic insights for human RASA3 (UniProt Q14644), with primary citations to the gathered literature.*

Notes on limitations and open questions
- While platelet and T‑cell data are strong, comprehensive definition of RASA3 regulation across diverse human tissues (including endothelium) and systematic human genetic association studies were not captured in the gathered 2023–2024 literature excerpts. Some regulatory aspects (e.g., precise PI3K dependence of membrane association) appear context-dependent and merit further investigation (odonoghue2024rolesofg pages 18-19). URL: https://doi.org/10.1042/BSR20231420 (May 2024).

References (URLs and dates embedded above)

References

1. (odonoghue2024rolesofg pages 18-19): Lorna O'Donoghue and Albert Smolenski. Roles of g proteins and their gtpase-activating proteins in platelets. Bioscience Reports, May 2024. URL: https://doi.org/10.1042/bsr20231420, doi:10.1042/bsr20231420. This article has 6 citations and is from a peer-reviewed journal.

2. (odonoghue2024rolesofg pages 10-11): Lorna O'Donoghue and Albert Smolenski. Roles of g proteins and their gtpase-activating proteins in platelets. Bioscience Reports, May 2024. URL: https://doi.org/10.1042/bsr20231420, doi:10.1042/bsr20231420. This article has 6 citations and is from a peer-reviewed journal.

3. (stefanini2015rasa3isa pages 1-2): Lucia Stefanini, David S. Paul, Raymond F. Robledo, E. Ricky Chan, Todd M. Getz, Robert A. Campbell, Daniel O. Kechele, Caterina Casari, Raymond Piatt, Kathleen M. Caron, Nigel Mackman, Andrew S. Weyrich, Matthew C. Parrott, Yacine Boulaftali, Mark D. Adams, Luanne L. Peters, and Wolfgang Bergmeier. Rasa3 is a critical inhibitor of rap1-dependent platelet activation. The Journal of clinical investigation, 125 4:1419-32, Apr 2015. URL: https://doi.org/10.1172/jci77993, doi:10.1172/jci77993. This article has 167 citations.

4. (stefanini2015rasa3isa pages 8-9): Lucia Stefanini, David S. Paul, Raymond F. Robledo, E. Ricky Chan, Todd M. Getz, Robert A. Campbell, Daniel O. Kechele, Caterina Casari, Raymond Piatt, Kathleen M. Caron, Nigel Mackman, Andrew S. Weyrich, Matthew C. Parrott, Yacine Boulaftali, Mark D. Adams, Luanne L. Peters, and Wolfgang Bergmeier. Rasa3 is a critical inhibitor of rap1-dependent platelet activation. The Journal of clinical investigation, 125 4:1419-32, Apr 2015. URL: https://doi.org/10.1172/jci77993, doi:10.1172/jci77993. This article has 167 citations.

5. (horitani2023thecriticalrole pages 1-2): Shunsuke Horitani, Yoshihiro Ueda, Yuji Kamioka, Naoyuki Kondo, Yoshiki Ikeda, Makoto Naganuma, and Tatsuo Kinashi. The critical role of rap1-gaps rasa3 and sipa1 in t cells for pulmonary transit and egress from the lymph nodes. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1234747, doi:10.3389/fimmu.2023.1234747. This article has 4 citations and is from a peer-reviewed journal.

6. (odonoghue2024rolesofg pages 17-18): Lorna O'Donoghue and Albert Smolenski. Roles of g proteins and their gtpase-activating proteins in platelets. Bioscience Reports, May 2024. URL: https://doi.org/10.1042/bsr20231420, doi:10.1042/bsr20231420. This article has 6 citations and is from a peer-reviewed journal.

## Citations

1. odonoghue2024rolesofg pages 10-11
2. horitani2023thecriticalrole pages 1-2
3. odonoghue2024rolesofg pages 18-19
4. odonoghue2024rolesofg pages 17-18
5. https://doi.org/10.1042/BSR20231420
6. https://doi.org/10.1172/jci77993
7. https://doi.org/10.3389/fimmu.2023.1234747
8. https://doi.org/10.1042/bsr20231420,
9. https://doi.org/10.1172/jci77993,
10. https://doi.org/10.3389/fimmu.2023.1234747,